| Literature DB >> 27216901 |
Ganesh Gopalakrishna1, Muaid H Ithman2, John Lauriello2.
Abstract
Although there has been more than 50 years of development, there remains a great need for better antipsychotic medications. This article looks at the recent advances in treatment of schizophrenia. New hypotheses have been suggested that may replace or complement the dopamine hypotheses. The article explores the different novel drugs that impact some of the key neurotransmitter systems currently. Phosphodiesterase 10A inhibitors and α-7 neuronal nicotinic acetylcholine receptor modulators constitute the majority. The marketing of these medications eventually may result in change about how schizophrenia is treated.Entities:
Keywords: Advances; Antipsychotics; Cognition; Negative symptoms; Schizophrenia
Mesh:
Substances:
Year: 2016 PMID: 27216901 DOI: 10.1016/j.psc.2016.01.005
Source DB: PubMed Journal: Psychiatr Clin North Am ISSN: 0193-953X